Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Turin, Italy.
Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université Catholique de Louvain, 1200 Brussels, Belgium.
Int J Mol Sci. 2020 Nov 14;21(22):8592. doi: 10.3390/ijms21228592.
Cachexia is a complication of dismal prognosis, which often represents the last step of several chronic diseases. For this reason, the comprehension of the molecular drivers of such a condition is crucial for the development of management approaches. Importantly, cachexia is a syndrome affecting various organs, which often results in systemic complications. To date, the majority of the research on cachexia has been focused on skeletal muscle, muscle atrophy being a pivotal cause of weight loss and the major feature associated with the steep reduction in quality of life. Nevertheless, defining the impact of cachexia on other organs is essential to properly comprehend the complexity of such a condition and potentially develop novel therapeutic approaches.
恶病质是一种预后不良的并发症,常代表着多种慢性疾病的终末阶段。因此,理解这种疾病的分子驱动因素对于开发管理方法至关重要。重要的是,恶病质是一种影响多种器官的综合征,常导致全身并发症。迄今为止,大多数恶病质的研究都集中在骨骼肌上,肌肉萎缩是体重减轻的关键原因,也是与生活质量急剧下降相关的主要特征。然而,明确恶病质对其他器官的影响对于正确理解这种疾病的复杂性并可能开发新的治疗方法至关重要。